Purpose: Targeted radionuclide therapy with 177Lu-PSMA-617 prolongs radiographical progression-free survival in prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), yet 13% of patients develop symptomatic skeletal events. The authors hypothesized that hemoglobin-based oxygen carriers (HBOCs) could potentiate 177Lu-PSMA-617 by reprogramming bone marrow (BM) immunity.
Methods:
Using PSMA-expressing xenografts, they demonstrated that concomitant HBOC administration significantly reduced tumor volume without increasing systemic toxicity. To dissect the underlying mechanism, the authors performed high-resolution single-cell RNA sequencing of murine BM.
Results:
HBOC treatment markedly expanded mature neutrophils, plasmacytoid dendritic cells, classical monocytes, natural killer T cells, and mature B cells, while concomitantly upregulating DNA damage repair genes such as Parp9, Dtx3l, and Smchd1 within these subsets. Gene set enrichment analysis confirmed significant activation of DNA damage response pathways, implying enhanced cellular radioresistance and improved tolerance to β-particle irradiation.
Conclusions:
Thus, HBOCs improve 177Lu-PSMA-617 antitumor efficacy indirectly via immune-subset expansion and DNA-repair reinforcement, offering a clinically feasible and safe strategy to optimize combination protocols for patients with mCRPC.
RaychaudhuriR, LinDW, MontgomeryRB. Prostate cancer: A review. JAMA.2025;333(16):1433–1446; doi: 10.1001/jama.2025.0228
2.
FallahJ, AgrawalS, GittlemanH, et al.FDA approval summary: Lutetium Lu 177 Vipivotide Tetraxetan for patients with metastatic castration-resistant prostate cancer. Clin Cancer Res.2023;29(9):1651–1657; doi: 10.1158/1078-0432.CCR-22-2875
3.
ArmstrongAJ, SartorO, de BonoJ, et al.Association of declining prostate-specific antigen levels with clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving [177Lu]Lu-PSMA-617 in the phase 3 VISION trial. Eur Urol2024;86(6):552–562; doi: 10.1016/j.eururo.2024.08.021
4.
DelkerA, FendlerWP, KratochwilC, et al.Dosimetry for (177)Lu-DKFZ-PSMA-617: A new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging.2016;43(1):42–51; doi: 10.1007/s00259-015-3174-7
5.
HennrichU, KopkaK. Lutathera®: The First FDA—and EMA-Approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel)2019;12(3):114; doi: 10.3390/ph12030114
6.
GroenerD, BaumgartenJ, HaefeleS, et al.Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement. Cancers (Basel)2021;13(16):4017; doi: 10.3390/cancers13164017
7.
KindF, MichalskiK, Yousefzadeh-NowshahrE, et al.Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression? EJNMMI Res2022;12(1):20; doi: 10.1186/s13550-022-00891-1
8.
HallqvistA, BrynjarsdóttirE, KrantzT, et al.177Lu-DOTATATE in combination with PARP inhibitor olaparib is feasible in patients with somatostatin-positive tumors: Results from the LuPARP Phase I Trial. J Nucl Med2025;66(5):707–712; doi: 10.2967/jnumed.124.268902
9.
ZangJ, LiuQ, SuiH, et al.177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer. J Nucl Med2020;61(12):1772–1778; doi: 10.2967/jnumed.120.242263
10.
ZhaiD, AnD, WanC, et al.Radiotherapy: Brightness and darkness in the era of immunotherapy. Transl Oncol2022;19:101366; doi: 10.1016/j.tranon.2022.101366
11.
ZhuK, WangL, XiaoY, et al.Nanomaterial-related hemoglobin-based oxygen carriers, with emphasis on liposome and nano-capsules, for biomedical applications: Current status and future perspectives. J Nanobiotechnology.2024;22(1):336; doi: 10.1186/s12951-024-02606-1
12.
HanidziarD, NakahoriY, CahillLA, et al.Characterization of pulmonary immune responses to hyperoxia by high-dimensional mass cytometry analyses. Sci Rep.2020;10(1):4677; doi: 10.1038/s41598-020-61489-y
13.
TaylorCT, ScholzCC. The effect of HIF on metabolism and immunity. Nat Rev Nephrol2022;18(9):573–587; doi: 10.1038/s41581-022-00587-8
14.
HiraniD, AlviraCM, DanopoulosS, et al.Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia. Eur Respir J2022;59(2):2002248; doi: 10.1183/13993003.02248-2020
15.
HanidziarD, RobsonSC. Hyperoxia and modulation of pulmonary vascular and immune responses in COVID-19. Am J Physiol Lung Cell Mol Physiol2021;320(1):L12–L16; doi: 10.1152/ajplung.00304.2020
16.
SpencerJA, FerraroF, RoussakisE, et al.Direct measurement of local oxygen concentration in the bone marrow of live animals. Nature2014;508(7495):269–273; doi: 10.1038/nature13034
17.
MacLaughlinKJ, BartonGP, MacLaughlinJE, et al.100% oxygen mobilizes stem cells and up-regulates MIF and APRIL in humans: A new point on the hormetic dose curve. Front Cell Dev Biol2024;12:1377203; doi: 10.3389/fcell.2024.1377203
18.
WangJ, PengZ, GuoJ, et al.CXCL10 recruitment of γδ T cells into the hypoxic bone marrow environment leads to IL17 expression and multiple myeloma progression. Cancer Immunol Res2023;11(10):1384–1399; doi: 10.1158/2326-6066.CIR-23-0088
19.
LudinA, Gur-CohenS, GolanK, et al.Reactive oxygen species regulate hematopoietic stem cell self-renewal, migration and development, as well as their bone marrow microenvironment. Antioxid Redox Signal2014;21(11):1605–1619; doi: 10.1089/ars.2014.5941
20.
JuntillaMM, PatilVD, CalamitoM, et al.AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species. Blood2010;115(20):4030–4038; doi: 10.1182/blood-2009-09-241000
21.
ZhangQ, MaY-X, DaiZ, et al.Tracking research on hemoglobin-based oxygen carriers: A scientometric analysis and in-depth review. Drug Des Devel Ther2023;17:2549–2571; doi: 10.2147/DDDT.S422770
22.
ZhuH, ChenJ, LiuK, et al.Human PBMC scRNA-seq-based aging clocks reveal ribosome to inflammation balance as a single-cell aging hallmark and super longevity. Sci Adv.2023;9(26):eabq7599; doi: 10.1126/sciadv.abq7599
23.
ZhongJ, MaoX, LiH, et al.Single-cell RNA sequencing analysis reveals the relationship of bone marrow and osteopenia in STZ-induced type 1 diabetic mice. J Adv Res.2022;41:145–158; doi: 10.1016/j.jare.2022.01.006
EvrardM, KwokIWH, ChongSZ, et al.Developmental analysis of bone marrow neutrophils reveals populations specialized in expansion, trafficking, and effector functions. Immunity2018;48(2):364–379.e368; doi: 10.1016/j.immuni.2018.02.002
26.
XieX, ShiQ, WuP, et al.Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. Nat Immunol2020;21(9):1119–1133; doi: 10.1038/s41590-020-0736-z
27.
MuenchDE, OlssonA, FerchenK, et al.Mouse models of neutropenia reveal progenitor-stage-specific defects. Nature2020;582(7810):109–114; doi: 10.1038/s41586-020-2227-7
28.
ChengY, SunQ, ChenY, et al.DTX3 suppresses bladder cancer cell invasion and metastasis by inhibiting the Notch signaling pathway. Int Immunopharmacol.2025;153:114529; doi: 10.1016/j.intimp.2025.114529
29.
ZhangL, YuX, ZhengL, et al.Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature2018;564(7735):268–272; doi: 10.1038/s41586-018-0694-x
30.
GugliettaS, KriegC. Phenotypic and functional heterogeneity of monocytes in health and cancer in the era of high dimensional technologies. Blood Rev.2023;58:101012; doi: 10.1016/j.blre.2022.101012
31.
KolabasZI, KuemmerleLB, PerneczkyR, et al.Distinct molecular profiles of skull bone marrow in health and neurological disorders. Cell2023;186(17):3706–3725.e3729; doi: 10.1016/j.cell.2023.07.009
32.
ZhaoL, PangY, ZhouY, et al.Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. Signal Transduct Target Ther.2024;9(1):142; doi: 10.1038/s41392-024-01853-w
33.
GuoX, ZhangY, ZhengL, et al.Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. Nat Med2018;24(7):978–985; doi: 10.1038/s41591-018-0045-3
34.
YuH, KouQ, YuanH, et al.Alkannin triggered apoptosis and ferroptosis in gastric cancer by suppressing lipid metabolism mediated by the c-Fos/SREBF1 axis. Phytomedicine2025;140:156604; doi: 10.1016/j.phymed.2025.156604
35.
SanliY, SimsekDH, SanliO, et al.177Lu-PSMA therapy in metastatic castration-resistant prostate cancer. Biomedicines.2021;9(4):430; doi: 10.3390/biomedicines9040430
36.
HofmanMS, EmmettL, SandhuS, et al.; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): A randomised, open-label, phase 2 trial. Lancet2021;397(10276):797–804; doi: 10.1016/S0140-6736(21)00237-3
37.
LoKK, BeyEA, PatraB, et al.Hemoglobin-based oxygen carrier mitigates transfusion-mediated pancreas cancer progression. Ann Surg Oncol.2013;20(6):2073–2077; doi: 10.1245/s10434-012-2842-0
38.
BelcherDA, LucasA, CabralesP, et al.Polymerized human hemoglobin facilitated modulation of tumor oxygenation is dependent on tumor oxygenation status and oxygen affinity of the hemoglobin-based oxygen carrier. Sci Rep.2020;10(1):11372; doi: 10.1038/s41598-020-68190-0
PabstR. The bone marrow is not only a primary lymphoid organ: The critical role for T lymphocyte migration and housing of long-term memory plasma cells. Eur J Immunol2018;48(7):1096–1100; doi: 10.1002/eji.201747392
41.
SunY, AliyariSR, ParvatiyarK, et al.STING directly interacts with PAR to promote apoptosis upon acute ionizing radiation-mediated DNA damage. Cell Death Differ2025;32(6):1167–1179; doi: 10.1038/s41418-025-01457-z
42.
HelmJS, RudelRA. Adverse outcome pathways for ionizing radiation and breast cancer involve direct and indirect DNA damage, oxidative stress, inflammation, genomic instability, and interaction with hormonal regulation of the breast. Arch Toxicol.2020;94(5):1511–1549; doi: 10.1007/s00204-020-02752-z
43.
ChangHHY, PannunzioNR, AdachiN, et al.Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol2017;18(8):495–506; doi: 10.1038/nrm.2017.48
44.
SantivasiWL, XiaF. Ionizing radiation-induced DNA damage, response, and repair. Antioxidants & Redox Signaling.2014;21(2):251–259; doi: 10.1089/ars.2013.5668
45.
YangC-S, JividenK, SpencerA, et al.Ubiquitin Modification by the E3 Ligase/ADP-Ribosyltransferase Dtx3L/Parp9. Mol Cell2017;66(4):503–516.e5; doi: 10.1016/j.molcel.2017.04.028
46.
TakeyamaK, AguiarRCT, GuL, et al.The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. The Journal of Biological Chemistry.2003;278(24):21930–21937.
47.
YanQ, DuttS, XuR, et al.BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. Mol Cell.2009;36(1):110–120; doi: 10.1016/j.molcel.2009.08.019
48.
YanQ, XuR, ZhuL, et al.BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8. Mol Cell Biol.2013;33(4):845–857; doi: 10.1128/MCB.00990-12
49.
BlewittME, GendrelA-V, PangZ, et al.SmcHD1, containing a structural-maintenance-of-chromosomes hinge domain, has a critical role in X inactivation. Nat Genet2008;40(5):663–669; doi: 10.1038/ng.142
50.
VančevskaA, AhmedW, PfeifferV, et al.SMCHD1 promotes ATM-dependent DNA damage signaling and repair of uncapped telomeres. Embo J2020;39(7):e102668; doi: 10.15252/embj.2019102668
51.
CokerH, BrockdorffN. SMCHD1 accumulates at DNA damage sites and facilitates the repair of DNA double-strand breaks. J Cell Sci.2014;127(Pt 9):1869–1874; doi: 10.1242/jcs.140020
52.
TangM, LiY, ZhangX, et al.Structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) promotes non-homologous end joining and inhibits homologous recombination repair upon DNA damage. J Biol Chem2014;289(49):34024–34032; doi: 10.1074/jbc.M114.601179
53.
Arroyo HorneroR, IdoyagaJ. Plasmacytoid dendritic cells: A dendritic cell in disguise. Mol Immunol.2023;159:38–45; doi: 10.1016/j.molimm.2023.05.007
54.
LeeJS, ParkS, JeongHW, et al.Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol2020;5(49):eabd1554; doi: 10.1126/sciimmunol.abd1554
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
